Volume 12.24 | June 25

2020-06-25 | MCN 12.24
Mammary Cell News by STEMCELL Technologies
Vol. 12.24 – 25 June, 2020
TOP STORY

Manumycin Polyketides Act as Molecular Glues between UBR7 and P53

Using chemoproteomic platforms, investigators showed that members of the manumycin family of polyketides, which bore multiple potentially reactive sites, targetted C374 of the putative E3 ligase UBR7 in breast cancer cells, and engaged in molecular glue interactions with the neosubstrate tumor-suppressor TP53, leading to p53 transcriptional activation and cell death.
[Nature Chemical Biology]

AbstractGraphical Abstract

Find the Right Antibodies For Your Stem Cell Research. Learn More
PUBLICATIONSRanked by the impact factor of the journal

FGFR4 Regulates Tumor Subtype Differentiation in Luminal Breast Cancer and Metastatic Disease

Scientists identified a subset of luminal A primary breast tumors that gave rise to HER2-enriched subtype metastases, but remained clinically HER2 negative. By testing the unique genetic and transcriptomic features of these cases, they developed the hypothesis that FGFR4 likely participated in this subtype switching.
[Journal of Clinical investigation]

AbstractGraphical Abstract

Chronic Circadian Disruption Modulates Breast Cancer Stemness and Immune Microenvironment to Drive Metastasis in Mice

The authors observed that circadian disruption significantly increased cancer-cell dissemination and lung metastasis. It also enhanced the stemness and tumor-initiating potential of tumor cells and created an immunosuppressive shift in the tumor microenvironment.
[Nature Communications]

Full Article

LNC942 Promoting METTL14-Mediated m6A Methylation in Breast Cancer Cell Proliferation and Progression

Researchers unveiled that LINC00942 exerted its functions as an oncogene in promoting METTL14-mediated m6A methylation and regulating the expression and stability of its target genes CXCR4 and CYP1B1 in breast cancer initiation and progression.
[Oncogene]

Abstract

KLF4 Defines the Efficacy of the Epidermal Growth Factor Receptor Inhibitor, Erlotinib, in Triple-Negative Breast Cancer Cells by Repressing the EGFR gene

Investigators report that krüppel-like factor 4 was a major determinant of epidermal growth factor receptor expression and activity in TNBC cells.
[Breast Cancer Research]

Full Article

YES1 Amplification Confers Trastuzumab–Emtansine (T-DM1) Resistance in HER2-Positive Cancer

The authors found that Yes was overexpressed in T-DM1–resistant cells owing to amplification of chromosome region 18p11.32, where the YES1 gene resides. Yes activated multiple proliferation-related signalling pathways, including EGFR, PI3K and MAPK, and led to cross-resistance to all types of HER2-targeted drugs, including antibody-drug conjugate, antibody and small molecule inhibitor.
[British Journal of Cancer]

Abstract

Gremlin-1 Augments the Oestrogen-Related Receptor α Signalling through EGFR Activation: Implications for the Progression of Breast Cancer

Researchers found that GREM1 knockdown inhibited the proliferation of breast cancer cells and xenograft mammary tumour growth, while its overexpression enhanced their viability, growth and invasiveness. Oestrogen-related receptor α, an orphan nuclear hormone receptor, directly interacted with the GREM1 promoter and increased the expression of GREM1.
[British Journal of Cancer]

Abstract

Cancer Cell Invasion of Mammary Organoids with Basal‐In Phenotype

Investigators described mammary organoids with a basal‐in phenotype where the basement membrane was located on the interior surface of the organoid.
[Advanced Healthcare Materials]

Abstract

Mechanical Strain Induces Phenotypic Changes in Breast Cancer Cells and Promotes Immunosuppression in the Tumor Microenvironment

Scientists demonstrated that exposure to mechanical strain promoted invasive and pro-tumorigenic phenotypes in breast cancer cells, indicating that mechanical strain could impact the growth and proliferation of cancer cell, alter exosome production by breast cancer, and induce immunosuppression in the tumor microenvironment by dampening anti-tumor immunity.
[Laboratory investigation]

Abstract

Virtual Conference Exhibition: Pluripotent Stem Cells
REVIEWS

Involvement of Glutathione Peroxidases in the Occurrence and Development of Breast Cancers

The authors focus on the molecular mechanism and function of glutathione peroxidases in the occurrence and development of breast cancer.
[Journal of Translational Medicine]

Full Article

INDUSTRY AND POLICY NEWS

Genentech’s Tecentriq in Combination With Chemotherapy (Including Abraxane) Meets Primary Endpoint of Improved Pathological Complete Response, Regardless of PD-L1 Status, as Initial Treatment for People with Early Triple-Negative Breast Cancer

Genentech announced that the Phase III IMpassion031 study, evaluating Tecentriq® in combination with chemotherapy in comparison to placebo plus chemotherapy, met its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in pathological complete response for the treatment of people with early triple-negative breast cancer, regardless of PD-L1 expression.
[Genetech]

Press Release

Gender Gap in Research Output Widens During Pandemic

A series of recent studies has demonstrated a significant drop in the productivity of female scientists, especially those early in their careers, relative to their male peers—and the gender gap is particularly pronounced for COVID-19 researchers.
[The Scientist]

Editorial

Graduate Programs Drop GRE after Online Version Raises Concerns about Fairness

Scores of academics have raised concerns about the equity of the online version of the test, arguing it disadvantages prospective students from rural and low-income backgrounds. “If I were … a student trying to take this exam, satisfying criteria would be extremely difficult for me,” says Emily Levesque, an assistant professor of astronomy at the University of Washington, Seattle.
[ScienceInsider]

Editorial

FEATURED EVENT

European Breast Cancer Conference

9/30/2020-10/2/2020 |
Barcelona, Spain

> See All Events

JOB OPPORTUNITIES

Staff Scientist – lmmunotherapy, Lymphocytes, Breast Cancer

National Cancer Institute – Bethesda, Maryland, United States

Research Fellow – Molecular Pharmacology

Mayo Clinic – Rochester, Minnesota, United States

Postdoctoral Fellow – Cancer Research

University of Oklahoma Health Science Center – Oklahoma City, Oklahoma, United States

Laboratory Research Technician – Breast Cancer

University of Vermont – Burlington, Vermont, United States

Staff Scientist – Cancer Systems Biology

City of Hope – Duarte, California, United States

> See All Jobs

Submit an article, publication, job or event
Brought to you by
stemcell-logo-for newsletter-2
Mammary Cell News Twitter